Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors

References

• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi: 10.3322/caac.21565.
   PubMed Web of Science ®Google Scholar
• Remick JS, Kowalski E, Samanta S, et al. Health-related quality of life and patient-reported outcomes in radiation oncology clinical trials. Curr Treat Options Oncol. 2020;21(11):87. doi: 10.1007/s11864-020-00782-4.
   PubMed Web of Science ®Google Scholar
• Ferrer M, Guedea F, Suárez JF, et al. Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up. Radiother Oncol. 2013;108(2):306–313. doi: 10.1016/j.radonc.2013.05.038.
   PubMed Web of Science ®Google Scholar
• Cozzarini C, Rancati T, Palorini F, et al. Patient-reported urinary incontinence after radiotherapy for prostate cancer: quantifying the dose–effect. Radiother Oncol. 2017;125(1):101–106. doi: 10.1016/j.radonc.2017.07.029.
   PubMed Web of Science ®Google Scholar
• Ohri N, Dicker AP, Showalter TN. Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol. 2012;19(4):6373–6380.
   PubMed Web of Science ®Google Scholar
• Rancati T, Fiorino C. Modelling radiotherapy side effects: practical applications for planning optimisation. 1st ed. Boca Raton (FL): CRC Press; 2019.
   Google Scholar
• Osoba D. Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults. Int J Cancer. 1999;83(S12):132–137. doi: 10.1002/(SICI)1097-0215(1999)83:12+<132::AID-IJC23>3.0.CO;2-4.
   Google Scholar
• Matzka M, Köck-Hódi S, Jahn P, et al. Relationship among symptom clusters, quality of life, and treatment-specific optimism in patients with cancer. Support Care Cancer. 2018;26(8):2685–2693. doi: 10.1007/s00520-018-4102-8.
   PubMed Web of Science ®Google Scholar
• Ma TM, Ballas LK, Wilhalme H, et al. Quality-of-Life outcomes and toxicity profile among patients with localized prostate cancer after radical prostatectomy treated with stereotactic body radiation: the SCIMITAR multicenter phase 2 trial. Int J Radiat Oncol Biol Phys. 2023;115(1):142–152. doi: 10.1016/j.ijrobp.2022.08.041.
   PubMed Web of Science ®Google Scholar
• Murthy V, Maitre P, Bhatia J, et al. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial. Radiother Oncol. 2020;145:71–80. doi: 10.1016/j.radonc.2019.12.006.
   PubMed Web of Science ®Google Scholar
• Hoffman KE, Penson DF, Zhao Z, et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323(2):149–163. doi: 10.1001/jama.2019.20675.
   PubMed Web of Science ®Google Scholar
• Ralph N, Ng SK, Zajdlewicz L, et al. Ten-year quality of life outcomes in men with prostate cancer. Psychooncology. 2020;29(2):444–449. doi: 10.1002/pon.5255.
   PubMed Web of Science ®Google Scholar
• Mazariego CG, Egger S, King MT, et al. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. BMJ. 2020;371:m3503. doi: 10.1136/bmj.m3503.
   PubMedGoogle Scholar
• Nakamura K, Konishi K, Komatsu T, et al. Quality of life after external beam radiotherapy for localized prostate cancer: comparison with other modalities. Int J Urol. 2019;26(10):950–954. doi: 10.1111/iju.14026.
   PubMed Web of Science ®Google Scholar
• Punnen S, Cowan JE, Chan JM, et al. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015;68(4):600–608. doi: 10.1016/j.eururo.2014.08.074.
   PubMed Web of Science ®Google Scholar
• Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–1424. doi: 10.1056/NEJMoa1606220.
   PubMed Web of Science ®Google Scholar
• Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–1437. doi: 10.1056/NEJMoa1606221.
   PubMed Web of Science ®Google Scholar
• Kerleau C, Guizard AV, Daubisse-Marliac L, et al. Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study. Eur J Cancer. 2016;63:143–153. doi: 10.1016/j.ejca.2016.05.020.
   PubMed Web of Science ®Google Scholar
• Lilleby W, Fosså SD, Waehre HR, et al. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys. 1999;43(4):735–743. doi: 10.1016/s0360-3016(98)00475-1.
   PubMed Web of Science ®Google Scholar
• Bacon CG, Giovannucci E, Testa M, et al. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer. 2002;94(3):862–871. doi: 10.1002/cncr.10248.
   PubMed Web of Science ®Google Scholar
• Schaake W, Wiegman EM, De Groot M, et al. The impact of gastrointestinal and genitourinary toxicity on health related quality of life among irradiated prostate cancer patients. Radiother Oncol. 2014;110(2):284–290. doi: 10.1016/j.radonc.2013.11.011.
   PubMed Web of Science ®Google Scholar
• Sveistrup J, Mortensen OS, Bjørner JB, et al. Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer. Radiat Oncol. 2016;11(1):117. doi: 10.1186/s13014-016-0689-4.
   PubMedGoogle Scholar
• Marvaso G, Gugliandolo SG, Bellerba F, et al. Phase II prospective trial “give me five” short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218). Med Oncol. 2020;37(8):37. doi: 10.1007/s12032-020-01397-3.
   PubMed Web of Science ®Google Scholar
• Vittrup AS, Kirchheiner K, Fokdal LU, et al. Reporting of late morbidity after radiation therapy in large prospective studies: a descriptive review of the current status. Int J Radiat Oncol Biol Phys. 2019;105(5):957–967. doi: 10.1016/j.ijrobp.2019.08.040.
   PubMed Web of Science ®Google Scholar
• Carillo V, Cozzarini C, Rancati T, et al. Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer. Radiother Oncol. 2014;111(1):100–105. doi: 10.1016/j.radonc.2014.02.006.
   PubMed Web of Science ®Google Scholar
• Palorini F, Cozzarini C, Gianolini S, et al. First application of a pixel-wise analysis on bladder dose-surface maps in prostate cancer radiotherapy. Radiother Oncol. 2016;119(1):123–128. doi: 10.1016/j.radonc.2016.02.025.
   PubMed Web of Science ®Google Scholar
• Improta I, Palorini F, Cozzarini C, et al. Bladder spatial-dose descriptors correlate with acute urinary toxicity after radiation therapy for prostate cancer. Phys Med. 2016;32(12):1681–1689. doi: 10.1016/j.ejmp.2016.08.013.
   PubMed Web of Science ®Google Scholar
• Onjukka E, Fiorino C, Cicchetti A, et al. Patterns in ano-rectal dose maps and the risk of late toxicity after prostate IMRT. Acta Oncol. 2019;58(12):1757–1764. doi: 10.1080/0284186X.2019.1635267.
   PubMed Web of Science ®Google Scholar
• Valdagni R, Vavassori V, Rancati T, et al. Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. Radiother Oncol. 2012;103(2):252–255. doi: 10.1016/j.radonc.2012.03.012.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365.
   PubMed Web of Science ®Google Scholar
• Kirchheiner K, Pötter R, Nout RA, et al. Late, persistent, substantial, Treatment-Related symptoms after radiation therapy (LAPERS): a new method for longitudinal analysis of late morbidity—applied in the EMBRACE study. Int J Radiat Oncol Biol Phys. 2020;106(2):300–309. doi: 10.1016/j.ijrobp.2019.10.027.
   PubMed Web of Science ®Google Scholar
• Vittrup AS, Tanderup K, Bentzen SM, et al. Persistence of late substantial patient-reported symptoms (LAPERS) after radiochemotherapy including image-guided adaptive brachytherapy for locally advanced cervical cancer: a report from the EMBRACE study. Int J Radiat Oncol Biol Phys. 2021;109(1):161–173. doi: 10.1016/j.ijrobp.2020.08.044.
   PubMed Web of Science ®Google Scholar
• Hopland-Nechita FV, Andersen JR, Beisland C. IPSS “bother question” score predicts health-related quality of life better than total IPSS score. World J Urol. 2022;40(3):765–772. doi: 10.1007/s00345-021-03911-2.
   PubMed Web of Science ®Google Scholar
• Fayers P, Bottomley A. Quality of life research within the EORTC-the EORTC QLQ-C30. European organisation for research and treatment of cancer. Eur J Cancer. 2002;38(4):S125–S33. doi: 10.1016/s0959-8049(01)00448-8.
   PubMedGoogle Scholar
• Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012;48(11):1713–1721. doi: 10.1016/j.ejca.2012.02.059.
   PubMed Web of Science ®Google Scholar
• Petersen SE, Thorsen LB, Hansen S, et al. A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients. Acta Oncol. 2022;61(2):179–184. doi: 10.1080/0284186X.2021.1979246.
   PubMed Web of Science ®Google Scholar
• Karlsdóttir Á, Muren LP, Wentzel-Larsen T, et al. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys. 2008;70(5):1478–1486. doi: 10.1016/j.ijrobp.2007.08.076.
   PubMed Web of Science ®Google Scholar
• Agasi-Idenburg SC, Thong MSY, Punt CJA, et al. Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer. Support Care Cancer. 2017;25(2):625–632. doi: 10.1007/s00520-016-3451-4.
   PubMed Web of Science ®Google Scholar
• Schellekens MPJ, Wolvers MDJ, Schroevers MJ, et al. Exploring the interconnectedness of fatigue, depression, anxiety and potential risk and protective factors in cancer patients: a network approach. J Behav Med. 2020;43(4):553–563. doi: 10.1007/s10865-019-00084-7.
   PubMed Web of Science ®Google Scholar
• Koitabashi R, Uchida Y. Analysing the relationship between cognition and urine storage function. Int J Urol Nurs. 2019;13(2):51–56. doi: 10.1111/ijun.12184.
   Google Scholar
• Bartlett L, Nowak M, Ho YH. Impact of fecal incontinence on quality of life. World J Gastroenterol. 2009;15(26):3276–3282. doi: 10.3748/wjg.15.3276.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Nakamura S, Nishimura T, et al. Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis. J Radiat Res. 2014;55(6):1033–1047. doi: 10.1093/jrr/rru061.
   PubMed Web of Science ®Google Scholar
• Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597–609. doi: 10.1038/nrclinonc.2014.127.
   PubMed Web of Science ®Google Scholar
• Donovan KA, Jacobsen PB. Fatigue, depression, and insomnia: evidence for a symptom cluster in cancer. Semin Oncol Nurs. 2007;23(2):127–135. doi: 10.1016/j.soncn.2007.01.004.
   PubMedGoogle Scholar
• Spampinato S, Tanderup K, Lindegaard JC, et al. Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors. Radiother Oncol. 2023;181:109501. doi: 10.1016/j.radonc.2023.109501.
   PubMed Web of Science ®Google Scholar
• van der Laan HP, Van den Bosch L, Schuit E, et al. Impact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer. Radiother Oncol. 2021;160:47–53. doi: 10.1016/j.radonc.2021.04.011.
   PubMed Web of Science ®Google Scholar
• Smet S, Spampinato S, Pötter R, et al. Risk factors for late persistent fatigue after chemoradiotherapy in patients with locally advanced cervical cancer: an analysis from the EMBRACE-I study. Int J Radiat Oncol Biol Phys. 2022;112(5):1177–1189. doi: 10.1016/j.ijrobp.2021.11.022.
   PubMed Web of Science ®Google Scholar
• Joseph N, Cicchetti A, McWilliam A, et al. High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer. Front Oncol. 2022;12:937934. doi: 10.3389/fonc.2022.937934.
   PubMed Web of Science ®Google Scholar
• Feigenberg SJ, Hanlon AL, Horwitz EM, et al. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62(2):397–405. doi: 10.1016/j.ijrobp.2004.10.021.
   PubMed Web of Science ®Google Scholar
• Taaffe DR, Newton RU, Spry N, et al. Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol. 2017;72(2):293–299. doi: 10.1016/j.eururo.2017.02.019.
   PubMed Web of Science ®Google Scholar
• Luo YH, Yang YW, Wu CF, et al. Fatigue prevalence in men treated for prostate cancer: a systematic review and meta-analysis. World J Clin Cases. 2021;9(21):5932–5942. doi: 10.12998/wjcc.v9.i21.5932.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Ohno T, Noguchi W, et al. Psychological distress and quality of life in cervical cancer survivors after radiotherapy do treatment modalities, disease stage, and self-esteem influence outcomes? Int J Gynecol Cancer. 2009;19(7):1264–1268. doi: 10.1111/IGC.0b013e3181a3e124.
   PubMed Web of Science ®Google Scholar
• Wenzel LB, Donnelly JP, Fowler JM, et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology. 2002;11(2):142–153. doi: 10.1002/pon.567.
   PubMed Web of Science ®Google Scholar
• Liu M, Harbaugh AG, Harring JR, et al. The effect of extreme response and non-extreme response styles on testing measurement invariance. Front Psychol. 2017;8:726. doi: 10.3389/fpsyg.2017.00726.
   PubMed Web of Science ®Google Scholar
• Cozzarini C, Rancati T, Badenchini F, et al. Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer. Strahlenther Onkol. 2016;192(5):297–304. doi: 10.1007/s00066-016-0964-1.
   PubMed Web of Science ®Google Scholar